Imfinzi (durvalumab)

CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Also, an increase in KIM-1 during therapy was linked to worse progression-free survival (HR 1.7; 95% CI, 1.13-2.58; p = 0.01) and OS (HR 1.95; 95% CI, 1.23-3.08; p = 0.004) in ccRCC. This exploratory analysis supports the utility of KIM-1 in advanced ccRCC and pRCC.

These updated European guidelines provide a comprehensive framework for standardized, high-quality care in stage I-III SCLC and establish a reference standard to harmonize radiotherapy approaches and inform the design of upcoming clinical trials.

P1, N=48, Recruiting, Washington University School of Medicine | Not yet recruiting --> Recruiting

Among 327 stage III NSCLC patients, 63.9% (n = 209) were unresected, 36.7% (n = 120) had a PD-L1-positive tumor, 18.3% (n = 60) completed chemoradiotherapy, and 11.3% (n = 37) initiated durvalumab. This is the first Belgian study to provide real-world insights into patient trajectories in lung cancer patients leveraging artificial intelligence technologies.

P2, N=101, Not yet recruiting, Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

P2, N=11, Completed, Brown University | Active, not recruiting --> Completed | Trial completion date: Oct 2026 --> Feb 2026

In EGFR-mutated unresectable stage III disease, durvalumab was not endorsed; osimertinib consolidation was favored. The only non-consensus item was adjuvant atezolizumab for PD-L1 ≥ 1% after platinum chemotherapy in EGFR/ALK - negative stage II - IIIA disease (AJCC 7th), lacking INVIMA approval at the time. This Delphi consensus provides a practical national framework for perioperative and unresectable stage III NSCLC management in Colombia.

P2, N=31, Active, not recruiting, Gruppo Oncologico del Nord-Ovest | Not yet recruiting --> Active, not recruiting

P1, N=200, Suspended, Amgen | Recruiting --> Suspended

Ceralasertib plus durvalumab was tolerated and associated with antitumour activity in advanced/metastatic NSCLC and HNSCC.

Current first-line therapy for advanced IDH1-mutant disease includes gemcitabine plus cisplatin combined with either durvalumab or pembrolizumab. Ivosidenib is commonly used as a second-line targeted therapy...More prospective clinical trials are needed to validate ctDNA-guided risk stratification, support treatment decisions on adjuvant therapy escalation or de-escalation, and enable treatment adaptation in IDH-mutant CCA, ultimately advancing precision oncology beyond the capabilities of imaging alone. This review aims to evaluate the potential of ctDNA-based MRD detection to refine precision treatment strategies in IDH-mutant CCA.

Our findings reveal regimen-specific systemic immune mechanisms in advanced HCC: Atez/Bev amplifies monocyte-NK cytotoxic axes, whereas Dur/Tre enhances monocyte-T cell inflammatory networks and TCR repertoire diversity. These insights highlight distinct predictive biomarkers and support regimen-tailored immunotherapy in HCC.